<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03928340</url>
  </required_header>
  <id_info>
    <org_study_id>FMBSUREC/05032019/Abd Alaziz</org_study_id>
    <nct_id>NCT03928340</nct_id>
  </id_info>
  <brief_title>Effect of Adding Metformin to Insulin Therapy on Pregnancy Outcomes in Women With Uncontrolled Type I Diabetes.</brief_title>
  <official_title>Effect of Adding Metformin to Insulin Therapy in Pregnant Women With Type I Diabetes as Regards Pregnancy Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amal Kotb Abdallah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amir Gabr</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mohamed Abdeltawwab Mahmoud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled clinical trial will be conducted in KasrELAiny hospitals, Cairo&#xD;
      University and Beni-Suef University Hospital, including 80 uncontrolled diabetic pregnant&#xD;
      women (type I) in the 3rd trimester (28-32 weeks of pregnancy) divided equally into study&#xD;
      group and control group, to compare the usage of both metformin and insulin instead of using&#xD;
      insulin alone. Group assignment will be randomized by computer program.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 80 uncontrolled diabetic pregnant patients in the 3rd trimester seeking medical&#xD;
      advice in Beni-Suef University Hospital and meet the eligibility criteria, are approached&#xD;
      about participation in the trial and given information pamphlets describing the study. The&#xD;
      patients are asked to sign a consent form and will be assigned to one of the 2 groups: Group&#xD;
      A (study group); will include 40 patients who will be treated with metformin&#xD;
&#xD;
      (1 gm twice daily (with the 2 main meals)), combined with insulin therapy Group B (control&#xD;
      group); will include 40 patients who will be treated with insulin alone. (Insulin dosage will&#xD;
      be adjusted according to endocrinological recommendations) All patients will be managed&#xD;
      according to NICE guidelines for diabetes with pregnancy (2015) Maternal assessment&#xD;
&#xD;
        -  Full history taking Baseline medical history is obtained along with other baseline&#xD;
           demographics and concomitant medications including insulin regimen and dose.&#xD;
&#xD;
        -  Thorough clinical examination Maternal weight, height and blood pressure measured and&#xD;
           recorded.&#xD;
&#xD;
        -  Laboratory investigations;&#xD;
&#xD;
             -  Routine labs: CBC, coagulation profile, liver and kidney function at time of&#xD;
                participation, 28-32 weeks of gestation especially renal parameter serum&#xD;
                Creatinine.&#xD;
&#xD;
             -  HbA1c at time of 1st examination.&#xD;
&#xD;
             -  FBS, 2h post prandial blood sugar will be done weekly from time of participation&#xD;
                till time of delivery&#xD;
&#xD;
        -  Fundus examination for early detection of retinal affection at Ophthalmology clinic&#xD;
&#xD;
      Follow up:&#xD;
&#xD;
        1. Fetal weight gain weekly&#xD;
&#xD;
        2. Maternal weight gain weekly&#xD;
&#xD;
      Accordingly:&#xD;
&#xD;
        1. Uncontrolled cases will follow up weekly in the High Risk Pregnancy outpatient clinic&#xD;
           until 36 weeks and then admitted to High risk pregnancy department for termination of&#xD;
           pregnancy&#xD;
&#xD;
           o Fetal surveillance will be done by ;CTG weekly, Ultrasound weekly and Fetal kick count&#xD;
           daily&#xD;
&#xD;
        2. Resistant uncontrolled cases will be admitted to high risk pregnancy department where&#xD;
           capillary blood sugar will be measured 7 times daily Fetal surveillance will be done by&#xD;
           ; CTG Daily, Ultrasound every 3 days and Fetal kick count daily&#xD;
&#xD;
      Assessment of Patients at time of termination by:&#xD;
&#xD;
        1. Fasting blood sugar , 2 hours post prandial blood sugar and HBA1C&#xD;
&#xD;
        2. Routine preoperative labs. CBC, coagulation profile, liver and kidney function&#xD;
&#xD;
        3. Fetal weight&#xD;
&#xD;
        4. Maternal weight Neonatal assessment after delivery include the following; APGAR score,&#xD;
           neonatal weight, incidence of transient tachypnea of newborn (TTN), acute respiratory&#xD;
           distress syndrome (ARDS), neonatal hypoglycemia and NICU admission.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Actual">March 29, 2020</completion_date>
  <primary_completion_date type="Actual">March 29, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>the change in level of glycosylated haemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>capillary glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>the change in level of glucose in capillary blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fasting blood sugar measurement.</measure>
    <time_frame>12 weeks</time_frame>
    <description>the change in level of glucose in venous blood after fasting for 8 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2 hours post prandial blood sugar measurement.</measure>
    <time_frame>12 weeks</time_frame>
    <description>the change in level of glucose in venous blood 2 hours after meal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal weight gain</measure>
    <time_frame>12 weeks</time_frame>
    <description>the change in mothers' weight in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weekly fetal weight gain measured by ultrasound</measure>
    <time_frame>12 weeks</time_frame>
    <description>the change of fetal weight measured by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin requirements</measure>
    <time_frame>12 weeks</time_frame>
    <description>the change in dose of insulin taken by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>attacks of maternal hypoglycemia</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of patients with plasma glucose level below 65 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intra uterine fetal death (IUFD)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of patients with death of fetus after 20 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change in neonatal weight in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>preterm birth</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of patients giving birth berfore 37 completed weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal respiratory distress</measure>
    <time_frame>12 weeks</time_frame>
    <description>the number of neonates with neonatal respiratory distress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal hypoglycemia</measure>
    <time_frame>12 weeks</time_frame>
    <description>the number of neonates with plasma glucose level below less than 45 mg/dL (2.5 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal Intensive care admission</measure>
    <time_frame>12 weeks</time_frame>
    <description>the number of neonates with neonatal Intensive care admission</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>combined metformin and insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>40 patients will be treated with metformin&#xD;
(1 gm twice daily (with the 2 main meals)), combined with insulin therapy</description>
    <arm_group_label>combined metformin and insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>40 patients will be treated with insulin alone. (Insulin dosage will be adjusted according to endocrinological recommendations)</description>
    <arm_group_label>Insulin only</arm_group_label>
    <arm_group_label>combined metformin and insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetic pregnant patients with type one diabetes and no other chronic disorders&#xD;
&#xD;
          -  Patients on insulin in the 3rd trimester of pregnancy (on insulin therapy since start&#xD;
             of gestation)&#xD;
&#xD;
          -  Patients pregnant in single living fetus with no apparent congenital anomalies&#xD;
&#xD;
          -  Haemoglobin A 1 C (HbA1c) level between 7% to 11%&#xD;
&#xD;
          -  All patients have done a dating ultrasound to confirm gestational age, viability and&#xD;
             rule out any abnormality&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with type 2 or gestational diabetes&#xD;
&#xD;
          -  Patients with intolerance or hypersensitivity to metformin&#xD;
&#xD;
          -  Patients with congestive heart failure or a history of congestive heart failure&#xD;
&#xD;
          -  Patients with renal insufficiency&#xD;
&#xD;
          -  Patients having current significant gastrointestinal problems such as severe vomiting&#xD;
             requiring intravenous fluids or hospitalization&#xD;
&#xD;
          -  Presence of acute or chronic metabolic acidosis, including diabetic ketoacidosis, a&#xD;
             history of diabetic ketoacidosis or history of lactic acidosis&#xD;
&#xD;
          -  Patients with liver impairment&#xD;
&#xD;
          -  Patients with known higher order pregnancies (twins, triplets, etc.)&#xD;
&#xD;
          -  Patients having a known potentially fetal lethal anomaly&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amal kotb</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beniswef university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amir Gabr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo university kasrelainy hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beniswef university hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 20, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2019</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Amira S Dieb</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

